Xuemin Qiu, Ling Wang, Yuyan Gui, Yingping Xu and Dajin Li
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Female Reproductive and Endocrine-related Disorders, Shanghai, China
Problems: Bu-shen Ning-xin Decoction (BSNXD), a traditional Chinese medicine compound, is used to treat postmenopausal osteoporotic women in clinical, prior to hormone replacement therapy without affecting uterus. How BSNXD affects bone metabolism is unclear.
Methods: C57BL/6 mice were ovariectomized, and afforded with Saline, BSNXD, 17β-estradiol, respectively. 12 weeks later, femurs were measured by micro-CT, and immune cells were analyzed by flow cytometry. MSCs were cultured with or without BSNXD serum, 14days later, osteoblast and adipocyte production were analyzed.
Results: BSNXD increased bone volume, bone mineral density, and bone trabecular numbers, but decreased bone trabecular spacing (p<0.05). BSNXD increased CTLA-4 and IL-10 expression, but did not affect Foxp3+ regulatory T cells (p<0.05). BSNXD serum increased ALP activity, but decreased adipocyte production,at the same time, Runx2, Collagen1, osterix, osteocalcin mRNA increased, and PPARr mRNA decreased.
Conclusions: BSNXD improves osteoporosis of ovariectomized mice by promoting osteoblast differentiation.